Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
JAMA Oncol. 2018 Apr 1;4(4):516-521. doi: 10.1001/jamaoncol.2017.4942.
Although oral contraceptive (OC) use is common, the influence of OC use on carcinogenesis is not fully understood. A recent Agency for Healthcare Research and Quality report identified a need to understand the consistency of OC use and cancer associations across subpopulations, including smokers and obese women.
To determine whether associations between duration of OC use and risk of specific cancers were modified by lifestyle characteristics.
DESIGN, SETTING, AND PARTICIPANTS: The prospective NIH-AARP Diet and Health Study (enrolled 1995-1996, followed until 2011), with population-based recruitment of AARP members in 6 states and 2 metropolitan areas. All analyses included at least 100 000 women who reported OC use at enrollment. We identified 1241 ovarian, 2337 endometrial, 11 114 breast, and 3507 colorectal cancer cases during follow-up. Data analysis was performed between September 2016 and April 2017.
Duration of OC use (never or <1 year [reference], 1-4, 5-9, or ≥10 years).
Development of ovarian, endometrial, breast, and colorectal cancers. We examined effect modification by modifiable lifestyle characteristics: cigarette smoking, alcohol consumption, body mass index (BMI), and physical activity. We used Cox models adjusted for age, race, age at menarche, and the modifiers of interest.
The analytic population was aged 50 to 71 years (median, 62 years) at enrollment and largely white (91%) and postmenopausal (96%). For ovarian cancer, OC use-associated risk reductions strengthened with duration of use (long-term OC use [≥10 years] HR, 0.60; 95% CI, 0.47-0.76; P < .001 for trend) and were similar across modifiable lifestyle factors. Risk reductions for endometrial cancer strengthened with duration of use (long-term OC use HR, 0.66; 95% CI, 0.56-0.78; P < .001 for trend); the most pronounced reductions were among long-term OC users who were smokers (HR, 0.47; 95% CI, 0.25-0.88), had obese BMIs (0.36; 95% CI, 0.25-0.52), and who exercised rarely (HR, 0.40; 95% CI, 0.29-0.56). Associations between OC use and breast and colorectal cancers were predominantly null.
Long-term OC use is consistently associated with reduced ovarian cancer risk across lifestyle factors. We observed the greatest risk reductions for endometrial cancer among women at risk for chronic diseases (ie, smokers, obese BMI). Oral contraceptive use may be beneficial for chemoprevention for a range of women with differing baseline cancer risks.
虽然口服避孕药(OC)的使用很常见,但 OC 使用对致癌作用的影响尚未完全了解。最近,医疗保健研究与质量局的一份报告指出,需要了解 OC 使用与癌症关联在亚人群中的一致性,包括吸烟者和肥胖女性。
确定 OC 使用时间与特定癌症风险之间的关联是否受生活方式特征的影响。
设计、设置和参与者:前瞻性 NIH-AARP 饮食与健康研究(1995-1996 年入组,随访至 2011 年),以 6 个州和 2 个大都市区的 AARP 成员为基础进行人群招募。所有分析均包括至少 100000 名在入组时报告使用 OC 的女性。我们在随访期间发现了 1241 例卵巢癌、2337 例子宫内膜癌、11114 例乳腺癌和 3507 例结直肠癌病例。数据分析于 2016 年 9 月至 2017 年 4 月进行。
OC 使用时间(从不或<1 年[参考],1-4 年,5-9 年或≥10 年)。
卵巢癌、子宫内膜癌、乳腺癌和结直肠癌的发展。我们通过可改变的生活方式特征(吸烟、饮酒、体重指数[BMI]和身体活动)来检验效果修饰。我们使用了调整年龄、种族、初潮年龄和感兴趣的修饰符的 Cox 模型。
分析人群的年龄在 50 至 71 岁之间(中位数为 62 岁),主要为白人(91%)和绝经后(96%)。对于卵巢癌,OC 使用相关风险随着使用时间的延长而降低(长期 OC 使用[≥10 年]HR,0.60;95%CI,0.47-0.76;P<0.001 趋势),且在可改变的生活方式因素方面相似。子宫内膜癌的风险降低随着使用时间的延长而增强(长期 OC 使用 HR,0.66;95%CI,0.56-0.78;P<0.001 趋势);在长期 OC 用户中,最显著的降低是吸烟者(HR,0.47;95%CI,0.25-0.88)、肥胖 BMI(0.36;95%CI,0.25-0.52)和很少运动(HR,0.40;95%CI,0.29-0.56)。OC 使用与乳腺癌和结直肠癌之间的关联主要为阴性。
长期 OC 使用与各种生活方式因素相关的卵巢癌风险降低一致。我们发现,对于有慢性疾病风险的女性(即吸烟者、肥胖 BMI),子宫内膜癌的风险降低最大。OC 使用可能对不同基线癌症风险的一系列女性具有化学预防作用。